Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q96J42
UPID:
TXD15_HUMAN
Alternative names:
-
Alternative UPACC:
Q96J42; D3DQA9; Q96MT2; Q9H639
Background:
Thioredoxin domain-containing protein 15 plays a pivotal role in ciliogenesis and acts as a positive regulator of ciliary hedgehog signaling. This protein's involvement in the formation and function of cilia underscores its significance in cellular processes.
Therapeutic significance:
Linked to Meckel syndrome 14, a disorder with renal cysts and developmental anomalies, understanding the role of Thioredoxin domain-containing protein 15 could open doors to potential therapeutic strategies.